(Q43908227)

27 November 2017

title

Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility. (English)

1 reference

27 November 2017

1 reference

3

N F Olivieri

1 reference

27 November 2017

G M Brittenham

1

1 reference

27 November 2017

D G Nathan

series ordinal

2

1 reference

27 November 2017

M J Pippard

series ordinal

4

1 reference

27 November 2017

D J Weatherall

series ordinal

5

1 reference

27 November 2017

language of work or name

English

0 references

publication date

1 January 2003

1 reference

27 November 2017

1 reference

27 November 2017

volume

361

1 reference

27 November 2017

issue

9352

1 reference

27 November 2017

page(s)

183; author reply 183-4

1 reference

Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912223-4

7 January 2021

Survival and disease complications in thalassemia major.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912223-4

7 January 2021

The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912223-4

7 January 2021

The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2912223-4

7 January 2021

10.1016/S0140-6736(03)12223-4

Identifiers

DOI

1 reference

27 November 2017

1 reference